Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
1.
Chem Biodivers ; 21(5): e202302096, 2024 May.
Artículo en Inglés | MEDLINE | ID: mdl-38412297

RESUMEN

Pistacia khinjuk is a species of flowering plants belonging to family Anacardiaceae, with promising pharmacological activities like antioxidants, anti-inflammatory, antiviral, and antimicrobial. This study aimed to investigate the GC-MS chemical composition of essential oil isolated from Pistacia khinjuk leaves and its inhibitory properties against aging-relevant enzymes such a collagenase and elastase. The isolated oil showed predominance of ß-cadinene (15.34 %), γ-amorphene (8.50 %), α-cadinol (8.14 %), τ-cadinol (7.57 %), (E)-ß-caryophyllene (5.77 %), α-pinene (4.70 %), phytol (4.57 %), α-muurolene (3.30 %), (+)-epi-bicyclosesquiphellandrene (3.21 %), and cubenene (3.16 %). Further, it showed remarkable inhibitory activities against collagenase and elastase with IC50 values of 15.61±0.69 and 41.12±2.09 µg/mL, respectively compared to epigallocatechin gallate (IC50=29.52±1.3 µg/mL and 26.86±1.37 µg/mL). as a conclusion, the leaf oil is recommended for topical cosmetic preparations to retard skin aging symptoms such as wrinkles. However, the bioavailability assessment and toxicological profile should be considered in the future studies.


Asunto(s)
Colagenasas , Cromatografía de Gases y Espectrometría de Masas , Aceites Volátiles , Elastasa Pancreática , Pistacia , Hojas de la Planta , Envejecimiento de la Piel , Hojas de la Planta/química , Aceites Volátiles/farmacología , Aceites Volátiles/química , Aceites Volátiles/aislamiento & purificación , Elastasa Pancreática/antagonistas & inhibidores , Elastasa Pancreática/metabolismo , Pistacia/química , Envejecimiento de la Piel/efectos de los fármacos , Colagenasas/metabolismo , Inhibidores Enzimáticos/farmacología , Inhibidores Enzimáticos/química , Inhibidores Enzimáticos/aislamiento & purificación , Humanos
2.
Ann Clin Lab Sci ; 54(3): 347-353, 2024 May.
Artículo en Inglés | MEDLINE | ID: mdl-39048169

RESUMEN

OBJECTIVE: Both chronic kidney disease and its main treatment, hemodialysis (HD), are associated with hematological abnormalities. However, little is known about how starting hemodialysis when already in end-stage renal disease (ESRD) affects hematological parameters. This study investigated the effect of HD on hematological and coagulation markers among ESRD patients. METHODS: A retrospective study was carried out on 43 HD-ESRD patients from January to December 2022. The data were collected from Sabt Alalaya General Hospital in Belgarn, Saudi Arabia. Using GraphPad Prism, multiple unpaired t-tests were utilized to compare hematological and coagulation markers between the patients and healthy subjects. RESULTS: The 43 HD-ESRD patients (46.5% male and 53.5% female) ranged in age from 20 to 89 years. The data obtained from our analysis unsurprisingly revealed significant variation in hematological parameters and coagulation patterns among HD-ESRD patients. Most notably, there were gradual and significant changes in platelet, MCV, MPV, and INR values during the assessment time. CONCLUSION: This investigation verified the possible occurrence of macrocytosis and thrombotic conditions among patients with ESRD who undergo HD. It is recommended to closely observe patients undergoing this procedure, with a specific focus on platelet, MCV, MPV, and INR levels as potential indications.


Asunto(s)
Relación Normalizada Internacional , Fallo Renal Crónico , Diálisis Renal , Humanos , Femenino , Fallo Renal Crónico/sangre , Fallo Renal Crónico/terapia , Fallo Renal Crónico/complicaciones , Masculino , Persona de Mediana Edad , Proyectos Piloto , Adulto , Anciano , Estudios Retrospectivos , Anciano de 80 o más Años , Plaquetas , Adulto Joven , Índices de Eritrocitos , Arabia Saudita/epidemiología , Coagulación Sanguínea/fisiología
3.
Saudi Med J ; 45(4): 414-423, 2024 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-38657987

RESUMEN

OBJECTIVES: To evaluate the association between transfusion-transmitted infections (TTIs) and ABO, Rh-D, and Kell blood systems among blood donors. METHODS: This was a retrospective study of 10,095 donors who visited the Blood Bank at Asir Hospital, Abha, Saudi Arabia. Data including demographic information, ABO, Rh-D, and Kell blood groups, and serological and molecular test results of TTIs (the TTIs were obtained from each donor's records). Chi-squared and Fisher's exact tests were employed to establish possible associations between blood groups and TTIs. RESULTS: The prevalence rate of TTIs among donors was 6.3%, with HBcAb (70%) being the most prevalent biomarker among positive donors. Donors with the O blood group were at a higher risk of contracting TTIs. Significant associations were observed between HIV and blood group A (χ2=6.30, p=0.01), HBsAg and group AB (χ2=17.3193, p=0.00003), malaria and group A (χ2=5.0567, p=0.02), and HBV-DNA and group AB (χ2=12.3163, p=0.0004). Also, Kell blood group was significantly associated with HIV (χ2=14.5, p=0.0001), HBcAb (χ2=78.51, p<0.0001), and syphilis (χ2=25.225, p<0.00001). CONCLUSION: ABO and Kell blood groups are associated with TTI markers. These findings highlight the need for improved strategies and approaches in screening and managing blood donations to minimize the risk of TTIs.


Asunto(s)
Sistema del Grupo Sanguíneo ABO , Donantes de Sangre , Sistema del Grupo Sanguíneo Rh-Hr , Humanos , Estudios Retrospectivos , Donantes de Sangre/estadística & datos numéricos , Arabia Saudita/epidemiología , Masculino , Femenino , Adulto , Sistema del Grupo Sanguíneo de Kell , Reacción a la Transfusión/epidemiología , Persona de Mediana Edad , Adulto Joven , Prevalencia , Malaria/epidemiología , Malaria/transmisión , Malaria/sangre , Adolescente
4.
Bone Marrow Transplant ; 59(5): 615-624, 2024 May.
Artículo en Inglés | MEDLINE | ID: mdl-38347187

RESUMEN

Allogeneic hematopoietic cell transplantation (allo-HCT) offers a curative option for patients with certain non-malignant hematological diseases. High-dose post-transplant cyclophosphamide (PT-Cy) (200 mg/kg) and sirolimus (3 mg/kg), (HiC) synergistically induce stable mixed chimerism. Further, sirolimus and cytotoxic T lymphocyte-associated antigen-4 immunoglobulin (CTLA4-Ig), also known as Abatacept (Aba), promote immune tolerance and allograft survival. Here, in a major histocompatibility complex (MHC)-mismatched allo-HCT murine model, we combined Aba and/or T-cell depleting anti-Thy1.2 (Thy) with a lower dose of PT-Cy (50 mg/kg) and Sirolimus (3 mg/kg), (LoC). While mice in the LoC group showed graft rejection, the addition of Thy to LoC induced similar donor chimerism levels when compared to the HiC group. However, the addition of Aba to LoC led to graft acceptance only in younger mice. When Thy was added to the LoC+Aba setting, graft acceptance was restored in both age groups. Engrafted groups displayed significantly reduced frequencies of recipient-specific interferon-γ-producing T cells as well as an increased frequency in regulatory T cells (Tregs) except in the LoC+Aba group. Splenocytes from engrafted mice showed no proliferation upon restimulation with Balb/c stimulators. Collectively, in combination with Aba or Thy, LoC may be considered to reduce graft rejection in patients who undergo allo-HCT.


Asunto(s)
Abatacept , Ciclofosfamida , Depleción Linfocítica , Sirolimus , Animales , Ciclofosfamida/farmacología , Sirolimus/farmacología , Ratones , Abatacept/farmacología , Abatacept/uso terapéutico , Trasplante de Células Madre Hematopoyéticas/métodos , Ratones Endogámicos BALB C , Quimera por Trasplante , Trasplante Homólogo/métodos , Aloinjertos
SELECCIÓN DE REFERENCIAS
Detalles de la búsqueda